Lanadelumab

Generic name: Lanadelumab
Brand names: Takhzyro
Drug class: Hereditary angioedema agents

Usage of Lanadelumab

Lanadelumab (Takhzyro) is a monoclonal antibody that works by reducing the activity of an enzyme that is uncontrolled in people with hereditary angioedema (a rare genetic immune system disorder). Lanadelumab is used to prevent attacks of hereditary angioedema (HAE) in patients who are 2 years of age and older.

People with hereditary angioedema have high levels of a substance called bradykinin, lanadelumab works by reducing the level of bradykinin, which helps to prevent the swelling and related symptoms of angioedema. Hereditary angioedema is an immune system condition that causes rapid swelling under the skin in areas such as the face, throat, arms, and legs. An attack of hereditary angioedema can be life-threatening if the swelling around the throat presses against the airway.

Lanadelumab-flyo (Brand name: Takhzyro) injection is FDA approved for patients who are 2 years of age and older to prevent attacks of hereditary angioedema. FDA approval was supported by data from HELP Study, the  HELP OLE Study and the Phase 3 SPRING Study (NCT SHP643-301).

Lanadelumab side effects

The most common lanadelumab side effects are:

  • injection site Reactions (pain, redness, and bruising)
  • upper respiratory infections
  • headache
  • rash
  • dizziness
  • diarrhea
  • muscle aches.

    • Lanadelumab may cause serious side effects, including allergic reactions. Allergic reactions may happen with lanadelumab. Call your healthcare provider or get emergency help right away if you have any of the following symptoms of allergic reactions:

  • wheezing
  • difficulty breathing
  • chest tightness
  • fast heartbeat
  • faintness
  • rash
  • hives

    • This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Lanadelumab

    You should not use lanadelumab if you are allergic to it or any of the inactive ingredients. For a full list of ingredients in Takhzyro see the Ingredients section at the bottom of this page.

    Lanadelumab is not approved for use by anyone younger than 2 years old.

    This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using lanadelumab.

    Pregnancy

  • If you are pregnant or planning to become pregnant. It is not known if lanadelumab can harm your unborn baby.
  • Tell your doctor if you are pregnant or plan to become pregnant.

    • Breastfeeding

  • If you are breastfeeding or plan to breastfeed. It is not known if lanadelumab passes into your breastmilk. 
  • Talk to your healthcare provider about the best way to feed your baby while using this  medicine.

    • Relate drugs

    How to use Lanadelumab

    Usual dose for adult and pediatric patients 12 years and older for hereditary angioedema:

  • Initial dose: 300 mg suBCUTAneously once every 2 weeks.
  • Maintenance dose: a 4-week dosing interval may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.

    • Usual dose for pediatric patients 6 years to less than 12 years old for hereditary angioedema:

  • Initial dose: 150 mg subcutaneously once every 2 weeks. 
  • Maintenance dose: a 4-week dosing interval may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.

    • Usual dose for pediatric patients 2 years to less than 6 years old dose for hereditary angioedema:

  • Dose: 150 mg administered subcutaneously every 4 weeks.
  • Self-injection is not recommended in children 2 years to less than 12 years.

    • What other drugs will affect Lanadelumab

    Other drugs may affect lanadelumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant